A Case of Immune Checkpoint Inhibitor–Induced Duodenitis
Open Access
- 1 October 2024
- journal article
- research article
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (10) , e01539
Abstract
Immune checkpoint inhibitors improve patient survival in multiple cancers, but immune-related adverse events, including new immunologic conditions arising during therapy, pose a significant challenge. Gastrointestinal immune-related adverse events, although common, exhibit diverse presentations. We present a case of duodenitis resembling celiac disease because of the anti–programmed cell death protein-1 antibody, pembrolizumab. Despite diagnostic uncertainty and therapeutic interventions, including gluten-free diet, symptoms stabilized even with resuming gluten. In addition, endoscopic abnormalities after pembrolizumab therapy have neither progressed nor completely resolved. This case underscores the need for investigation into the pathogenesis of immune checkpoint inhibitor–induced duodenitis, with implications for care of patients on immunotherapies.Keywords
This publication has 15 references indexed in Scilit:
- Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseasesJournal of Cancer Research and Clinical Oncology, 2023
- Pembrolizumab-induced antiTTG IgA-negative duodenitis treated with gluten withdrawalEuropean Journal of Gastroenterology & Hepatology, 2021
- Immune checkpoint inhibitor-associated celiac diseaseJournal for ImmunoTherapy of Cancer, 2020
- Gastrointestinal adverse events associated with immune checkpoint inhibitor therapyGastroenterology Report, 2019
- Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitorsRheumatology, 2019
- A case of checkpoint inhibitor-induced celiac diseaseJournal for ImmunoTherapy of Cancer, 2019
- Interplay between Type 1 Diabetes Mellitus and Celiac Disease: Implications in TreatmentDigestive Diseases, 2018
- A Pitfall in Suspected (refractory) Celiac Disease: Losartan-Induced EnteropathyAmerican Journal of Gastroenterology, 2017
- Clinical and Histologic Mimickers of Celiac DiseaseClinical and Translational Gastroenterology, 2017
- Immunogenetics of type 1 diabetes: A comprehensive reviewJournal of Autoimmunity, 2015